Your browser doesn't support javascript.
loading
Decreased salivary lactoferrin levels are specific to Alzheimer's disease.
González-Sánchez, Marta; Bartolome, Fernando; Antequera, Desiree; Puertas-Martín, Veronica; González, Pilar; Gómez-Grande, Adolfo; Llamas-Velasco, Sara; Herrero-San Martín, Alejandro; Pérez-Martínez, David; Villarejo-Galende, Alberto; Atienza, Mercedes; Palomar-Bonet, Miriam; Cantero, Jose Luis; Perry, George; Orive, Gorka; Ibañez, Borja; Bueno, Hector; Fuster, Valentin; Carro, Eva.
Afiliação
  • González-Sánchez M; Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain; Neurology Service Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Bartolome F; Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain. Electronic address: fbartolome.imas12@h12o.es.
  • Antequera D; Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain.
  • Puertas-Martín V; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; CIBER de Enfermedades Cardiovasculares, Madrid, Spain; Hospital Universitario 12 de Octubre Research Institute (imas12), Madrid, Spain.
  • González P; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; CIBER de Enfermedades Cardiovasculares, Madrid, Spain; Hospital Universitario 12 de Octubre Research Institute (imas12), Madrid, Spain.
  • Gómez-Grande A; Nuclear Medicine Service, Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain.
  • Llamas-Velasco S; Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain; Neurology Service Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Herrero-San Martín A; Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain; Neurology Service Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Pérez-Martínez D; Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain; Neurology Service Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Villarejo-Galende A; Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain; Neurology Service Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Atienza M; Laboratory of Functional Neuroscience, Pablo de Olavide University, Seville, Spain, CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, Spain.
  • Palomar-Bonet M; Laboratory of Functional Neuroscience, Pablo de Olavide University, Seville, Spain, CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, Spain.
  • Cantero JL; Laboratory of Functional Neuroscience, Pablo de Olavide University, Seville, Spain, CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, Spain.
  • Perry G; Department of Biology and Neurosciences Institute, University of Texas at San Antonio, San Antonio, TX, USA.
  • Orive G; Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country, Vitoria, Spain; Networked Center for Biomedical Research in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain.
  • Ibañez B; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain, CIBER de Enfermedades Cardiovasculares, Madrid, Spain; IIS-Fundacion Jiménez Díaz Hospital, Madrid, Spain.
  • Bueno H; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain, CIBER de Enfermedades Cardiovasculares, Madrid, Spain; Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain; Hospital Universitario 12 de Octubre Research Institute (imas12), Cardiology Department
  • Fuster V; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; Icahn School of Medicine at Mount Sinai, New York, New York, United States.
  • Carro E; Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain. Electronic address: carroeva@h12o.es.
EBioMedicine ; 57: 102834, 2020 Jul.
Article em En | MEDLINE | ID: mdl-32586758
ABSTRACT

BACKGROUND:

Evidences of infectious pathogens in Alzheimer's disease (AD) brains may suggest a deteriorated innate immune system in AD pathophysiology. We previously demonstrated reduced salivary lactoferrin (Lf) levels, one of the major antimicrobial proteins, in AD patients.

METHODS:

To assess the clinical utility of salivary Lf for AD diagnosis, we examine the relationship between salivary Lf and cerebral amyloid-ß (Aß) load using amyloid-Positron-Emission Tomography (PET) neuroimaging, in two different cross-sectional cohorts including patients with different neurodegenerative disorders.

FINDINGS:

The diagnostic performance of salivary Lf in the cohort 1 had an area under the curve [AUC] of 0•95 (0•911-0•992) for the differentiation of the prodromal AD/AD group positive for amyloid-PET (PET+) versus healthy group, and 0•97 (0•924-1) versus the frontotemporal dementia (FTD) group. In the cohort 2, salivary Lf had also an excellent diagnostic performance in the health control group versus prodromal AD comparison AUC 0•93 (0•876-0•989). Salivary Lf detected prodromal AD and AD dementia distinguishing them from FTD with over 87% sensitivity and 91% specificity.

INTERPRETATION:

Salivary Lf seems to have a very good diagnostic performance to detect AD. Our findings support the possible utility of salivary Lf as a new non-invasive and cost-effective AD biomarker.

FUNDING:

Instituto de Salud Carlos III (FIS15/00780, FIS18/00118), FEDER, Comunidad de Madrid (S2017/BMD-3700; NEUROMETAB-CM), and CIBERNED (PI2016/01) to E.C.; Spanish Ministry of Economy and Competitiveness (SAF2017-85310-R) to J.L.C., and (PSI2017-85311-P) to M.A.; International Centre on ageing CENIE-POCTEP (0348_CIE_6_E) to M.A.; Instituto de Salud Carlos III (PIE16/00021, PI17/01799), to H.B.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glândulas Salivares / Doença de Alzheimer / Disfunção Cognitiva / Lactoferrina Tipo de estudo: Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glândulas Salivares / Doença de Alzheimer / Disfunção Cognitiva / Lactoferrina Tipo de estudo: Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article